Please assess the completion status of the following clinical trial:

Trial Title: BIOSOLVE-IV Magmaris Swiss Satellite Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is ≥18 years of age~* Subject must be willing to sign a Patient Informed Consent~* Symptomatic coronary artery disease~* Subject with a maximum of two single de novo lesions in two different major epicardial vessels~* Target lesion length ≤ 21 mm by QCA or by visual estimation~* Target lesion stenosis \>50% and \<100% by visual estimation, and TIMI flow ≥1.~* Subject is eligible for Dual Anti Platelet Therapy (DAPT)~* Reference vessel diameter between 2.7-3.7 mm by visual estimation, depending on the scaffold size used~Exclusion Criteria:~* Pregnant and/or breastfeeding females or females who intend to become pregnant during the time of the registry~* Known allergies to: Acetylsalicylic Acid (ASA), clopidogrel, heparin or any other anticoagulant /antiplatelet required for PCI, contrast medium, sirolimus, or similar drugs; or the scaffold materials including Magnesium, Yttrium, Neodymium, Zirconium, Gadolinium, Dysprosium, Tantalum that cannot be adequately pre-medicated~* Subjects on dialysis~* Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST elevation myocardial infarction (STEMI) within 72 hours prior to the index procedure. Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment~* Documented left ventricular ejection fraction (LVEF) ≤30% as documented within maximum 6 months prior to the procedure~* Heavily calcified or extremely tortuous lesions~* Bifurcation lesion requiring side branch intervention, if side branches \>2 mm in diameter are involved~* Restenotic target lesion~* Thrombus in target vessel~* Target lesion is located in or supplied by a diseased (defined as vessel irregularity per angiogram and \>20% stenosed lesion by visual estimation) arterial or venous bypass graft~* Left main coronary artery disease~* Ostial target lesion (within 5.0 mm of vessel origin)~* Target vessel (including side branches) has second lesion which requires treatment according to the investigator's discretion~* Unsuccessful pre-dilatation, defined as residual stenosis rate \>20% by visual estimation and/or angiographic complications (e.g. distal embolization, side branch closure, extensive dissections)~* Planned surgery within 6 months of PCI unless dual antiplatelet therapy will be maintained~* Currently participating in another study and primary endpoint is not reached yet~* Planned interventional treatment of any non-target vessel within 30 days post procedure~* Planned intervention of the target vessel within 6-month after the index procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues